Ascilion
Jeremy Bost currently serves as Head of Clinical Affairs at Ascilion and is a member of the Consortium Council at Next Generation ImmunoDermatology. As the Founder of Bristers Spring Holdings, Jeremy demonstrates entrepreneurial leadership. Previous roles include Director of Research & Barrier Indications and Product Manager at SciBase, where coordination of clinical research and product development for Nevisense technology occurred within the dermatology diagnostic space. Jeremy’s experience also encompasses serving as a Deputy Board Member at Sensorbee, and a PhD student specializing in Synthetic Biology, Genetic, and Cell Therapies at Karolinska Institutet. Earlier research involvement includes positions at the Broad Institute of MIT and Harvard and the University of Oxford. Jeremy holds a PhD in Medicine from Karolinska Institutet and a Bachelor of Science in Biomedical/Medical Engineering from Wentworth Institute of Technology.
This person is not in any teams
This person is not in any offices
Ascilion
Ascilion is the world leader in sampling of dermal interstitial fluid (dISF). A pioneer within hollow microneedle technology since 2012, Ascilion has developed the only solution available for sampling of practical amounts of pure dISF, enabling complete quantitative biomarker evaluation. Ascilion’s product PELSA is painless, quick, easy to use and leaves no residual mark on the skin. PELSA is available for research use and for pharmaceutical or cosmetic testing applications.